Related Experiment Video
Updated: Jul 8, 2025

Iterative Development of an Innovative Smartphone-Based Dietary Assessment Tool: Traqq
Published on: March 19, 2021
Methodological guidelines and publications of benefit-risk assessment for health technology assessment: a scoping
Bruna De Oliveira Ascef1, Franciele Cordeiro Gabriel2, Erica Aranha Suzumura2,3
1Departamento de Medicina Preventiva, Faculdade de Medicina, FMUSP, Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil brunaascef16@gmail.com.
Background:
Benefit-risk assessment (BRA) is used in multiple phases along the health technology's life-cycle to evaluate the balance between the benefits and risks, as it is fundamental to all stakeholders. BRA and its methodological approaches have been applied primarily in the context of regulatory agencies. However, BRA's application and extent in the context of health technology assessment (HTA) bodies remain less clear. Our goal is to perform a scoping review to identify and map methodological guidelines and publications on methods of BRA. This will be done considering the different phases of the life-cycle of health technologies to underline both the depth and extent of research concerning BRA, especially in the context of HTA.
Methods And Analysis:
This scoping review protocol was developed following the framework proposed by Arksey and O'Malley, and the updated guidelines by the Joanna Briggs Institute. We will include methodological publications that provide recommendations or guidelines on methods for BRA. We will conduct electronic searches on Medline (PubMed) and EMBASE (Ovid) databases; manual searches on the main websites of HTA bodies and drug regulatory organisations; and contact experts in the field. Systematic extraction forms will be used to screen and assess the identified publications by independent assessors. We will provide a qualitative synthesis using descriptive statistics and visual tools. Results will be summarised in systematic evidence tables and comparative evidence scoping charts.
Ethics And Dissemination:
This review will use data publicly available and does not require ethics approval. The results of this scoping review will contribute to scientific knowledge and act as a basis for methodologists, guideline developers and researchers for the development of BRA to inform regulatory decisions, reimbursement and coverage decision making. The results will be disseminated through peer-reviewed articles, conferences, policy briefs and workshops.
Trial Registration Number:
Open Science Framework (https://doi.org/10.17605/OSF.IO/69T3V).
More Related Videos
11:38High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
Published on: May 10, 2016
14:43A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Hazard Ratio
For example, in a clinical trial...
Pre-Procedural Guidelines for Assessing Blood Pressure
Clinical Trials
There are four phases in a clinical trial. A phase one...